Topics

Intellia Therapeutics, Inc. Company Profile

07:36 EDT 18th September 2019 | BioPortfolio

Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. Intellia intends to advance its pipeline and potentially develop a new drug class by leveraging its leading scientific and clinical development expertise and its exclusive access to one of the most comprehensive intellectual property platforms available. Intellia is supported by its founding investors Atlas and Novartis, as well a number of public and private sector funds. In 2014, Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. In September 2015, Intellia was named a “Fierce 15” biotech company by FierceBiotech. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.


News Articles [924 Associated News Articles listed on BioPortfolio]

Intellia Therapeutics Presents New Data at Genetics Meeting

Intellia Therapeutics will showcase the first demonstration of targeted gene insertion with CRISPR/Cas9 in the liver of non-human primates during its presentation at American Society of Gene and Cel...

Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer

CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) —  Intellia Therapeutics, Inc., (NASDAQ:NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its new executive vice president and chief scientific off...

New CRISPR Fight: Old Friends Intellia, Caribou in License Dispute

An epic legal battle over CRISPR-Cas9 genome editing ended last year. But another one, smaller in scope and involving two long-time CRISPR allies, has quietly begun. Last October, Intellia Therapeutic...

Intellia Therapeutics (NTLA) Investor Presentation - Slideshow

Intellia Therapeutics to Participate at June Healthcare Investor Conferences

CAMBRIDGE, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technolo...

Intellia Therapeutics to Present at August Healthcare Investor Conference

CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technol...

Intellia Therapeutics, Inc. 2019 Q2 - Results - Earnings Call Slides

Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update

Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosisExpects to...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [427 Associated PubMed Articles listed on BioPortfolio]

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Glycan analysis for protein therapeutics.

Glycosylation can be a critical quality attribute for protein therapeutics due to its extensive impact on product safety and efficacy. Glycan characterization is important in the process of protein dr...

Clinical Trials [185 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1368 Associated Companies listed on BioPortfolio]

Intellia Therapeutics, Inc.

Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. Intellia inten...

Intellia Therapeutics

Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technolo...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Intellia Therapeutics, Inc." on BioPortfolio

We have published hundreds of Intellia Therapeutics, Inc. news stories on BioPortfolio along with dozens of Intellia Therapeutics, Inc. Clinical Trials and PubMed Articles about Intellia Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intellia Therapeutics, Inc. Companies in our database. You can also find out about relevant Intellia Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record